BR0114196A - Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas. - Google Patents

Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.

Info

Publication number
BR0114196A
BR0114196A BR0114196-1A BR0114196A BR0114196A BR 0114196 A BR0114196 A BR 0114196A BR 0114196 A BR0114196 A BR 0114196A BR 0114196 A BR0114196 A BR 0114196A
Authority
BR
Brazil
Prior art keywords
thiazolidine
pyridyl
ethoxy
benzyl
amino
Prior art date
Application number
BR0114196-1A
Other languages
English (en)
Inventor
Prabhakar Chebiyyam
Ramabhadra Sarma Mamillapalli
Vyas Krishnamurthi
Vishnuvardhan Reddy Seella
Om Reddy Gaddam
Original Assignee
Reddy S Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy S Res Foundation filed Critical Reddy S Res Foundation
Publication of BR0114196A publication Critical patent/BR0114196A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

"FORMAS POLIMóRFICAS DE MALEATO DE 5-[4-[2-[N-METIL-N-(2-PIRIDIL)AMINO]ETóXI] BENZIL] TIAZOLIDINA-2,4-DIONA E PROCESSO PARA A PREPARAçãO DAS MESMAS". Esta invenção refere-se a novas formas polimórficas e pseudo-polimórficas do maleato de 5-[4-[2-[N-metil-N-(2-piridil)amino]etóxi]benzil] tiazolidina-2,4-diona e os que tenham a fórmula (1). A invenção também refere-se a uma composição farmacêutica que compreende a nova forma polimórfica ou a misturas das mesmas e um veículo farmaceuticamente aceitável. As formas polimórficas da presente invenção são mais ativas, como um agente antidiabético, do que o maleato de 5-[4-[2-[N-metil-N-(2-piridil)amino]etóxi]benzil]tiazolidina-2,4-diona conhecido até agora.
BR0114196-1A 2000-09-26 2001-09-25 Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas. BR0114196A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN805CH2000 2000-09-26
PCT/US2001/029896 WO2002026737A1 (en) 2000-09-26 2001-09-25 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation

Publications (1)

Publication Number Publication Date
BR0114196A true BR0114196A (pt) 2003-07-22

Family

ID=29266775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114196-1A BR0114196A (pt) 2000-09-26 2001-09-25 Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.

Country Status (15)

Country Link
EP (1) EP1322647A1 (pt)
JP (1) JP2004509961A (pt)
AU (1) AU9123201A (pt)
BR (1) BR0114196A (pt)
CA (1) CA2426117A1 (pt)
CZ (1) CZ2003864A3 (pt)
HU (1) HUP0301161A3 (pt)
IL (1) IL155036A0 (pt)
MX (1) MXPA03002580A (pt)
NO (1) NO324968B1 (pt)
NZ (1) NZ525498A (pt)
PL (1) PL360661A1 (pt)
SK (1) SK3752003A3 (pt)
WO (1) WO2002026737A1 (pt)
ZA (1) ZA200303223B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
WO2000064892A2 (en) 1999-04-23 2000-11-02 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
PL351684A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
WO2004062667A1 (en) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
EP1753759A2 (en) * 2004-03-31 2007-02-21 Sandoz AG Novel co-precipitate of amorphous rosiglitazone
CN1956981A (zh) * 2004-05-11 2007-05-02 参天制药株式会社 角膜结膜病变治疗剂
JP2005350451A (ja) * 2004-05-11 2005-12-22 Santen Pharmaceut Co Ltd 角結膜障害治療剤
CZ296472B6 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
EP0844997A1 (en) * 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
CN1221417A (zh) * 1996-07-26 1999-06-30 雷迪博士研究基金会 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
PL351684A1 (en) * 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
WO2000064892A2 (en) * 1999-04-23 2000-11-02 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic

Also Published As

Publication number Publication date
WO2002026737A8 (en) 2003-11-06
HUP0301161A2 (hu) 2003-11-28
NO20031356L (no) 2003-05-26
WO2002026737A1 (en) 2002-04-04
AU9123201A (en) 2002-04-08
EP1322647A1 (en) 2003-07-02
JP2004509961A (ja) 2004-04-02
CZ2003864A3 (cs) 2004-01-14
NZ525498A (en) 2004-11-26
CA2426117A1 (en) 2002-04-04
SK3752003A3 (sk) 2005-03-04
NO324968B1 (no) 2008-01-14
PL360661A1 (en) 2004-09-20
IL155036A0 (en) 2003-10-31
ZA200303223B (en) 2004-07-26
MXPA03002580A (es) 2003-10-15
NO20031356D0 (no) 2003-03-25
HUP0301161A3 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
HUP0204122A2 (hu) Dioxo-tiazolidint és hetformint tartalmazó gyógyszerkészítmény és felhasználása
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
BR0107564A (pt) Composição de gliburida
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BR0010683A (pt) Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo
SE0001899D0 (sv) New compounds
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
BR0108870A (pt) Sais cloridrato de 5-[4-[2-(n-metil-n-(2-piridil) amino) etoxi] benzil] tiazolidino-2,4-diona
BR0010914A (pt) Composto medicamento agente profilático ou terapêutico, e, uso do composto
KR950703953A (ko) 2-아미노-6-n-프로필아미노-4, 5, 6, 7-테트라하이드로벤조티아졸(프라미펙솔)의 항우울제로서의 용도(Use of 2-amino-6-n-propylamino-4, 5, 6, 7-tetrahydrobenzothiazole (pramipexol)as an antidepressant drug)
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
DK149852C (da) Analogifremgangsmaade til fremstilling af substituerede 3-aminosydnoniminer eller et farmakologisk acceptabelt syreadditionssalt deraf
BRPI0211635B8 (pt) composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
SE9902937D0 (sv) Pharmaceutical compositions
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
DK1446404T3 (da) Rosiglitazonedisylater og deres anvendelse som antidiabetika
EA200300234A1 (ru) Тартратные соли производного тиазолидиндиона
SE9902936D0 (sv) Pharmaceutical compositions
BR9915835A (pt) Composição farmacêutica, e, processo para a preparação de uma composição
HUP0003463A2 (hu) Piperidinil-metil-oxazolidinon-származék, eljárás ennek előállítására és a vegyületet tartalmazó gyógyszerkészítmény
FR2812547B1 (fr) Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: DR. REDDY S LABORATORIES LIMITED (IN)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]